🇺🇸 FDA
Patent

US 6369235

Substituted benzimidazoles, and methods of use thereof, for the inhibition of HIV reverse transcription and for the treatment of HIV infection

expired A61PA61P31/18A61P37/04

Quick answer

US patent 6369235 (Substituted benzimidazoles, and methods of use thereof, for the inhibition of HIV reverse transcription and for the treatment of HIV infection) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Apr 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Apr 09 2002 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P31/18, A61P37/04, A61P43/00